XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - USD ($)
1 Months Ended 3 Months Ended
Jul. 08, 2021
Dec. 31, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable     $ 0   $ 5,159,000
Novo Nordisk          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share Purchase Agreement, Upfront Payment $ 60,000,000        
Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones     1,130,000,000    
Revenue from License and Intellectual Property, Share Purchase Agreement     0 $ 0  
Milestone achievement, Clinical milestone   $ 40,000,000      
Accounts Receivable, after Allowance for Credit Loss     $ 0   $ 0
Novo Nordisk | Transition services          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from License and Intellectual Property, Share Purchase Agreement $ 700,000